Wells Fargo & Company Metacrine, Inc. Transaction History

Wells Fargo & Company

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$0.35 - $0.46 $2 - $2	6 Added 2.55%	241 $0
Q3 2022 Nov 14, 2022	BUY	$0.43 - $0.55 $18 - $23	42 Added 21.76%	235 $0
Q2 2022 Aug 12, 2022	BUY	$0.36 - $0.63 $6 - $10	17 Added 9.66%	193 $0
Q1 2022 May 16, 2022	BUY	$0.43 - $0.7 $41 - $67	96 Added 120.0%	176 $0
Q4 2021 Feb 14, 2022	BUY	$0.64 - $3.83 $0 - $3	1 Added 1.27%	80 $0
Q3 2021 Nov 15, 2021	SELL	$2.61 - $3.84 $1,787 - $2,630	-685 Reduced 89.66%	79 $0
Q2 2021 Aug 16, 2021	SELL	$3.37 - $5.73 $4,391 - $7,466	-1,303 Reduced 63.04%	764 $3,000
Q1 2021 May 13, 2021	SELL	$6.2 - $11.0 $8,636 - $15,323	-1,393 Reduced 40.26%	2,067 $13,000
Q4 2020 Feb 09, 2021	BUY	$7.75 - $11.42 $26,815 - $39,513	3,460 New	3,460 $27,000

Ticker MTCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,569,500
Description
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.